Unitaid, a part of the WHO, engaged the UW’s TLC-ART program for developing a grant agreement (GAD). It intends to accelerate the global impact of long-acting (LA) HIV medicines enabled by TLC-ART innovations. The project will transform current oral drugs into more effective, targeted LA therapies to improve patient appeal.
Category: News
Dr. Rodney Ho Presents T-Cell Webinar to 500+ Scientists
On 8/8/2019 Dr. Rodney Ho presented a Webinar on T-Cells to an audience of over 500 to the American Chemical Society (ACS) titled “Transformation of Recombinant Cells to FDA Approved Products: Clinical Development to Marketplace.”
Rodney Ho recognized with AACP Volwiler Research Achievement Award
Dr. Rodney Ho was named recipient of the American Association of Colleges of Pharmacy (AACP) Volwiler Research Achievement Award. Rodney is the second UWSOP faculty member to receive this prestigious award. The award ceremony took place in Chicago, IL on Monday, July 15th.
Swiss Acad of Pharm Sci (SAPhS)
Prof. Borchard, President of SAPhS invited Dr. Ho to deliver a lecture at the Univ of Geneva. The presentation was entitled, “Targeted drug-combination nanoparticles for long-acting application in HIV and Cancer.”
GPEN conference; Singapore
At the 2018 GPEN 1 conference in Singapore, Dr. Rodney Ho and Jesse Yu, a graduate student presented TLC-ART research progress. Jesse’s presented his work on, “Novel drug combination matrix in solid states enabled by stable interactions of hydrophilic and hydrophobic HIV drug combination plus lipid excipients.” Dr. Ho’s held a workshop entitled, “Development and Validation of a MBPK (mechanism-based pharmacokinetic) Model to guide complex injectable drug-combination products”. Sept. 2018
1 GPEN, Globalization of Pharmaceutics Education Network (GPEN); the meeting was organized by students assisted by faculty advisers for the sole purpose of fostering and facilitating international pharmaceutical science exchange.
Luminary Award, CIE
Dr. Ho received the Luminary Innovator Award from CIE 1. He was recognized in Sept 2018 in Bellevue, WA for his innovations in science and product development. Sept. 2018
1 CIE is the Chinese Institute of Engineers. CIE Seattle promotes academic and professional excellence in the Asian Pacific American community through programs advancing innovation, collaboration and education.
Scientific Advisors, TLC-ART
Thank-You Board Advisors–Flexner, Becker, Chen, Robert, Nicoll-Griffith and PO’s- D Livnat, H Zhang, M Protopopova for their input in the 2018 annual Scientific Advisory Board meeting. We also have benefited from input of Drs. Z Gu and D Zhang on an IND-enabling plan. Their support and guidance are much appreciated as the program is planning for a first-in-human study in the near future. Oct. 2018
Global WACh, Children and Women
TLC-ART Director Dr. Rodney Ho shared at the Global WACh 1 2018–Bioengineering forum to develop drugs for Children and Women. Dr. Ho spoke on systems approach to targeted, long-acting and drug combinations as an engineering solutions for HIV intended for women and children. Oct. 2018
1 WACh stands for the Global Center for the Integrated Health of Women, Adolescents and Children.
CROI
TLC-ART PI’s Drs. Collier and Ho discussed innovation in first-in-human study at the 2018 Conference on Retroviruses & Opportunistic Infections (CROI).
Dr. Jane Simone
Dr. Jane Simone presented HIV-patient preferences on long-acting-injectable treatment. Her presentation at UCLA was titled, “Getting to 2020: Top Challenges in Biobehavioral HIV Prevention”.